Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/27/2025

Hemoglobin Measurement as the First‑Line Investigation in Children with Suspected Thalassemia Major

Pathophysiology of the Clinical Triad

  • Skull (frontal) bossing results from massive bone‑marrow expansion that attempts to compensate for chronic severe anemia. 1
  • Maxillary enlargement (“chipmunk facies”) is produced by the same marrow hyperplasia mechanism. 2
  • Hepatosplenomegaly develops secondary to extramedullary hematopoiesis and iron overload associated with chronic severe anemia. 1
  • Chronic severe anemia in thalassemia major drives growth failure through multiple pathways: tissue hypoxia, endocrine dysfunction from iron deposition (pituitary, thyroid, gonads), nutritional deficiencies, and the metabolic burden of ineffective erythropoiesis. 2

Diagnostic Priority of Hemoglobin

  • A markedly low hemoglobin level (typically < 7 g/dL in untreated thalassemia major) provides immediate diagnostic confirmation and explains all associated clinical findings. 1
  • Hemoglobin measurement alone determines the etiology of short stature, whereas pituitary‑hormone testing evaluates a secondary consequence rather than the primary disorder. 3

Guideline Recommendations (American College of Medical Genetics – ACMG)

  • When physical examination reveals dysmorphic features and organomegaly, the evaluation must first identify the underlying syndrome before pursuing isolated short‑stature work‑up. 2
  • Testing pituitary function before confirming the hematologic disorder is discouraged; the primary focus should be on confirming severe anemia. 4
  • Liver‑function tests may reflect iron overload but do not establish the primary diagnosis; they should be ordered after hemoglobin confirms thalassemia. 1

Clinical Approach Algorithm

Critical Pitfall to Avoid

  • Do not initiate isolated short‑stature investigations (bone age, IGF‑1, growth‑hormone stimulation) when characteristic dysmorphic features are present; the ACMG guidelines mandate prioritizing identification of the underlying hematologic condition. 5